DeepMed Research

Boryung Pharmaceutical Co., Ltd.

🇰🇷South Korea

Country: 🇰🇷South Korea

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Fimasartan and Rosuvastatin for Hypertension and Dyslipidemia Control

Completed

Conditions: Cardiovascular Diseases
Hyperlipidemias

First Posted Date: 2016-09-26

Last Posted Date: 2023-06-12

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 541

Registration Number: NCT02913794

Locations: 🇰🇷
Severance Hospital, Seoul, Korea, Republic of

A Study to Compare the Pharmacokinetics of Lafutidine and Irsogladine Maleate Tablet

Phase 1

Completed

Conditions: Gastric Ulcer

Interventions: Drug: BRI-1501
Drug: Lafutidine
Drug: Irsogladine maleate

First Posted Date: 2016-05-03

Last Posted Date: 2017-02-07

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 34

Registration Number: NCT02759224

Locations: 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of Fimasartan and Rosuvastatin in Healthy Male Subjects

Phase 1

Completed

Conditions: Hypertension

Interventions: Drug: Fimasartan
Drug: Rosuvastatin
Drug: Fimasartan + Rosuvastatin

First Posted Date: 2016-03-10

Last Posted Date: 2018-11-02

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 36

Registration Number: NCT02704702

A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

Phase 3

Completed

Conditions: Chronic Kidney Disease

Interventions: Drug: Fimsartan 60mg~120mg
Drug: Losartan 50mg~100mg

First Posted Date: 2015-12-03

Last Posted Date: 2022-05-25

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 351

Registration Number: NCT02620306

Locations: 🇰🇷
Severance hospital, Seoul, Korea, Republic of

The Drug-drug Interaction and Safety of Lafutidine and Irsogladine Maleate in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Peptic Ulcer

Interventions: Drug: Lafutidine
Drug: Irsogladine maleate

First Posted Date: 2015-10-21

Last Posted Date: 2017-02-06

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 24

Registration Number: NCT02581696

Locations: 🇰🇷
The Catholic University of Korea, Seoul St.Mary's Hospital, Seoul, Korea, Republic of

A Study to Compare the Pharmacokinetics and Safety of a Fixed Dose Combination of Fimasartan/Amlodipine/Rosuvastatin

Phase 1

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: Fimasartan/Amlodipine/Rosuvastatin
Drug: Fimasartan/Amlodipine
Drug: Rosuvastatin

First Posted Date: 2015-10-07

Last Posted Date: 2016-02-24

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 100

Registration Number: NCT02569814

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

A Study to Compare the Pharmacokinetics of Fimasartan/Atorvastatin Combination Tablet

Phase 1

Completed

Conditions: Hyperlipidemia
Hypertension

Interventions: Drug: Fimasartan/Atorvastatin Combination Tablet
Drug: Fimasartan
Drug: Atorvastatin

First Posted Date: 2015-10-02

Last Posted Date: 2016-02-25

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 99

Registration Number: NCT02566187

Locations: 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

Long-term Immunogenicity and Safety of Fourth Administration of Boryung Cell-Culture Japanese Encephalitis Vaccineinj

Phase 4

Completed

Conditions: Japanese Encephalitis

Interventions: Biological: Japanese encephalitis vaccine

First Posted Date: 2015-08-26

Last Posted Date: 2017-02-06

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 94

Registration Number: NCT02532569

Locations: 🇰🇷
Wonju Sevrance Christian Hospital, Wonju, Gangwon-do, Korea, Republic of
🇰🇷
Ewha Womans University Mokdong Hospital, Seoul, Korea, Republic of
🇰🇷
Inha University Hospital, Incheon, Korea, Republic of

and more 6 locations

Fimasartan Achieving SBP Target (FAST) Study

Phase 4

Completed

Conditions: Essential,Hypertension

Interventions: Drug: Placebo
Drug: Valsartan
Drug: Fimasartan
Drug: Olmesartan medoxomil

First Posted Date: 2015-07-13

Last Posted Date: 2017-07-05

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 369

Registration Number: NCT02495324

Locations: 🇰🇷
The Catholic University of Korea,Uijeongbu St.Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
🇰🇷
The Catholic University of Korea, St. Paul's Hospital, Seoul, Dongdaemun-gu, Korea, Republic of
🇰🇷
The Catholic University of Korea, St.Vincent's Hospital., Suwon-si, Gyeonggi-do, Korea, Republic of

and more 5 locations

A Clinical Study to Evaluate the Pharmacokinetics of Lozanoc and Sporanox in Korean Healthy Male Volunteers

Phase 1

Completed

Conditions: Dermatomycoses
Superficial Mycoses
Histoplasmosis
Candidiasis

Interventions: Drug: Sporanox 100mg
Drug: Lozanoc 50mg

First Posted Date: 2015-07-09

Last Posted Date: 2016-03-04

Lead Sponsor: Boryung Pharmaceutical Co., Ltd

Target Recruit Count: 24

Registration Number: NCT02493738

Locations: 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy